You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday.
Telehealth providers stay nimble amid regulatory uncertainty
A handful of online abortion medication providers told me they were anxiously awaiting the Supreme Court’s ruling on mifepristone last week — a decision that risks dramatically altering their operations by limiting the types of medication they could dispense via mail. Mifepristone is often used in combination with misopristol to end a pregnancy, though misopristol can also be used on its own.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect